The immune checkpoint blockade (ICB) by ICIs is an emerging active immunotherapy for TNBC, while in the HER+ breast cancer subset, passive immunotherapy with monoclonal antibodies against HER-2 family receptors has been carried out for a long time. This evidence concerns the gene ERBB2 and breast carcinoma.